Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
NCT07008963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48
Last updated 2026-02-23
Summary
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Conditions
Interventions
- OTHER
-
non-interventional
This is a non-interventional, observational study
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-31
- Primary Completion
- 2025-11-28
- Completion
- 2025-11-28
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
NCT06339281 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663 ·Status: RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00036868 ·Status: COMPLETED ·Phase: PHASE2
-
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
NCT04942899 ·Status: UNKNOWN ·Phase: PHASE2
-
Capecitabine in Women With Operable Breast Cancer
NCT00148720 ·Status: TERMINATED ·Phase: PHASE2
-
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
NCT00684983 ·Status: COMPLETED ·Phase: PHASE2
-
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
NCT00968968 ·Status: TERMINATED ·Phase: PHASE3
-
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
NCT05063136 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
NCT03561740 ·Status: RECRUITING ·Phase: PHASE3
-
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
NCT00095706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
NCT00077363 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT04965064 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
NCT01615068 ·Status: COMPLETED
-
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907 ·Status: COMPLETED ·Phase: PHASE1
-
Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer
NCT01924078 ·Status: UNKNOWN ·Phase: PHASE2
-
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
NCT00019812 ·Status: COMPLETED ·Phase: PHASE2
-
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
NCT06961331 ·Status: COMPLETED
-
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
NCT06607757 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
NCT01808573 ·Status: COMPLETED ·Phase: PHASE3
-
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
NCT01526512 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
NCT00022672 ·Status: COMPLETED ·Phase: PHASE3
-
Lapatinib Resistance in Patients With Breast Cancer
NCT00898573 ·Status: WITHDRAWN
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
NCT01332981 ·Status: COMPLETED
-
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
NCT02177175 ·Status: COMPLETED ·Phase: PHASE2